PEOPLE - Eragen makes appointment:
This article was originally published in Clinica
Executive Summary
Molecular diagnostics firm Eragen (Madison, Wisconsin) has appointed Miguel Blanc as vice-president of corporate development. With more than ten years' experience in this specialist area, Mr Blanc joins the firm from GE Healthcare, where he was manager of global business development and played a role in several major acquisitions for the $3bn biosciences division during his tenure there. His list of achievements includes completing the strategic assessment and due diligence for GE's entry into the life sciences market through the $11bn-acquisition of Amersham in 2004, and being instrumental in the (ultimately aborted) $8.13bn acquisition of Abbott Labs' diagnostics and POC divisions.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.